Defunct Company
Total Trials
9
As Lead Sponsor
7
As Collaborator
2
Total Enrollment
527
NCT01247194
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 31, 2010
Completion: Jun 30, 2011
NCT01448200
A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
Start: Oct 31, 2011
Completion: Nov 30, 2012
NCT01786382
A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole
Start: Feb 28, 2013
Completion: Mar 31, 2013
NCT01859962
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
Phase: Phase 2
Start: May 31, 2013
Completion: Dec 31, 2014
NCT01928147
A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
Start: Aug 31, 2013
Completion: Nov 30, 2015
NCT01979484
Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations
Start: Oct 31, 2013
Completion: Dec 31, 2013
NCT02258321
Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations
Start: Oct 31, 2014
NCT06100003
A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Gastric Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method
Phase: N/A
Role: Collaborator
Start: Oct 18, 2023
Completion: Dec 1, 2025
NCT06100016
A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Colorectal Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method